Circulating calprotectin and S100A8/A9-related biomarkers for diagnosis and prognostic stratification in adult acute infection and sepsis: a systematic review and meta-analysis.
- 1Department of Anesthesiology, Zigong Fourth People's Hospital, Zigong, Sichuan, China.
- 2Department of Anesthesiology, Zigong Hospital of Chengdu University of Traditional Chinese Medicine, Zigong, Sichuan, China.
Abstract
Circulating calprotectin is a proposed marker of acute innate immune activation, but reported diagnostic and prognostic performance is inconsistent. We assessed circulating calprotectin and S100A8/A9-related biomarkers for diagnosing acute infection and sepsis and stratifying prognosis in adults. We searched biomedical databases and trial registries through July 4, 2026, for adult studies of circulating calprotectin/S100A8/A9 in acute infection or sepsis. Random-effects models pooled diagnostic and reported prognostic areas under the receiver operating characteristic curve (AUC). Threshold-based sensitivity and specificity were analyzed separately using bivariate random-effects models. We used the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess diagnostic risk of bias and evidence certainty. Exploratory subgroup, sensitivity, biomarker-comparison, and combined-model analyses were also performed. Twenty-two reports representing 21 independent cohorts were included. The primary diagnostic meta-analysis yielded a pooled AUC of 0.741 (95% confidence interval [CI], 0.657-0.810). The pooled AUC was 0.703 (95% CI, 0.600-0.789) for sepsis and 0.758 (95% CI, 0.636-0.849) for acute infection or infection-source-related outcomes. In separate threshold-based analyses, pooled sensitivity and specificity were 0.70 (95% CI, 0.46-0.86) and 0.57 (95% CI, 0.55-0.59) for sepsis, and 0.46 (95% CI, 0.09-0.88) and 0.86 (95% CI, 0.60-0.96) for acute infection or infection-source-related outcomes, respectively. For mortality/survival outcomes, pooled sensitivity and specificity were 0.72 (95% CI, 0.65-0.77) and 0.66 (95% CI, 0.53-0.77), respectively, while the pooled reported prognostic AUC was 0.737 (95% CI, 0.688-0.786). Exploratory analyses were directionally stable, but paired biomarker comparisons did not provide definitive evidence of superiority. Certainty was very low for all major outcomes. Circulating calprotectin and S100A8/A9-related biomarkers provide moderate, context-dependent information in adult acute infection and sepsis. They may serve as adjunctive host-response markers, particularly for selected infection/source contrasts, but current evidence does not support stand-alone diagnosis, universal thresholds, or replacement of established biomarkers and clinical assessment. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261441569, identifier CRD420261441569.
Related
- RAS Mutations as Prognostic Biomarkers in Digestive Cancers: From Binary Classification to Variant-Specific and Context-Dependent Risk Stratification
- Hemodynamic biomarkers in symptomatic intracranial atherosclerotic stenosis: evidence boundaries and research pathways from prognostic stratification to treatment-effect prediction
- Blood-based inflammatory biomarkers in ovarian cancer: addressing the challenge of early detection, metastasis, and prognostic stratification.
- Immune and Circulating Biomarkers in Hepatocellular Carcinoma: Prognostic and Predictive Relevance for Immunotherapy
- Serum Prokineticin-2 and Calprotectin as Potential Biomarkers of Disease Stage and Focal Organ Involvement in Human Brucellosis: A Prospective Case–Control Study
BibTeX
@article{liao2026circulating,
title = {{Circulating calprotectin and S100A8/A9-related biomarkers for diagnosis and prognostic stratification in adult acute infection and sepsis: a systematic review and meta-analysis.}},
author = {Yin-Sheng Liao and Yu-Ping Deng and Jian-Li Song and Xuan Yu and Qiang Li and Bin Lu and Guan-Yu Chen},
journal = {Frontiers in cellular and infection microbiology},
year = {2026},
month = oct,
doi = {10.3389/fcimb.2026.1934020},
url = {https://europepmc.org/article/MED/42952930},
note = {CC BY},
}
RIS
TY - JOUR
TI - Circulating calprotectin and S100A8/A9-related biomarkers for diagnosis and prognostic stratification in adult acute infection and sepsis: a systematic review and meta-analysis.
AU - Yin-Sheng Liao
AU - Yu-Ping Deng
AU - Jian-Li Song
AU - Xuan Yu
AU - Qiang Li
AU - Bin Lu
AU - Guan-Yu Chen
PY - 2026
DA - 2026/10/14
JO - Frontiers in cellular and infection microbiology
DO - 10.3389/fcimb.2026.1934020
UR - https://europepmc.org/article/MED/42952930
AB - Circulating calprotectin is a proposed marker of acute innate immune activation, but reported diagnostic and prognostic performance is inconsistent. We assessed circulating calprotectin and S100A8/A9-related biomarkers for diagnosing acute infection and sepsis and stratifying prognosis in adults. We searched biomedical databases and trial registries through July 4, 2026, for adult studies of circulating calprotectin/S100A8/A9 in acute infection or sepsis. Random-effects models pooled diagnostic and reported prognostic areas under the receiver operating characteristic curve (AUC). Threshold-based sensitivity and specificity were analyzed separately using bivariate random-effects models. We used the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess diagnostic risk of bias and evidence certainty. Exploratory subgroup, sensitivity, biomarker-comparison, and combined-model analyses were also performed. Twenty-two reports representing 21 independent cohorts were included. The primary diagnostic meta-analysis yielded a pooled AUC of 0.741 (95% confidence interval [CI], 0.657-0.810). The pooled AUC was 0.703 (95% CI, 0.600-0.789) for sepsis and 0.758 (95% CI, 0.636-0.849) for acute infection or infection-source-related outcomes. In separate threshold-based analyses, pooled sensitivity and specificity were 0.70 (95% CI, 0.46-0.86) and 0.57 (95% CI, 0.55-0.59) for sepsis, and 0.46 (95% CI, 0.09-0.88) and 0.86 (95% CI, 0.60-0.96) for acute infection or infection-source-related outcomes, respectively. For mortality/survival outcomes, pooled sensitivity and specificity were 0.72 (95% CI, 0.65-0.77) and 0.66 (95% CI, 0.53-0.77), respectively, while the pooled reported prognostic AUC was 0.737 (95% CI, 0.688-0.786). Exploratory analyses were directionally stable, but paired biomarker comparisons did not provide definitive evidence of superiority. Certainty was very low for all major outcomes. Circulating calprotectin and S100A8/A9-related biomarkers provide moderate, context-dependent information in adult acute infection and sepsis. They may serve as adjunctive host-response markers, particularly for selected infection/source contrasts, but current evidence does not support stand-alone diagnosis, universal thresholds, or replacement of established biomarkers and clinical assessment. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261441569, identifier CRD420261441569.
SN - 2235-2988
ER -